Plasma endogenous secrection receptor for advanced glycation end products of type 2 diabetes patients is associated with diabetic peripheral neuropathy

Abstract

Objective To compare the plasma endogenous secrection receptor for advanced glycation end products (esRAGE) level between normal subjects and type 2 diabetes mellitus (T2DM) patients, and to investigate whether the esRAGE is associated with diabetic peripheral neuropathy in T2DM patients. Methods A total of 24 cases of normal subjects and 61 cases of T2DM patients were involved in the study, and then the patients were divided into two groups, that was, patients with diabetic peripheral neuropathy (DPN) group and without diabetic peripheral neuropathy (non–DPN) group. Plasma esRAGE was measured with Enzyme linked immunosorbent assay (ELISA). Myoelectricity evoked potential equipment was applied to detect nerve conduction studies. Blood pressure, body mass index, fasting plasma glucose, HbA1c, and plasma lipids level were measured as well. Student t test and nonparametric statistics were applied to analysis data between two groups and the related factors of DPN were investigated with logistic regression analysis. Results The plasma esRAGE level did not show significant difference between normal subjects and T2DM patients ((0.28±0.13) μg/L vs (0.25±0.15) μg/L, P>0.05). However there was significant different between DPN group and non–DPN group in patients ((0.21±0.14) μg/L vs (0.33±0.13) μg/L, P<0.05). The logistic regression analysis showed DPN was associated with age, HbA1c, and esRAGE in T2DM patients. Conclusions The plasma esRAGE level has not significant difference between T2DM patients and normal subjects. The plasma esRAGE level is a protective factor for DPN , on the contrary age and HbA1c are risk factors for DPN in T2DM patients. Key words: Diabetes mellitus; Endogenous secrection receptor for advanced glycation end products; Diabetic peripheral neuropathy